Amarin Corporation Reports 7.4% Revenue Growth and Improved Net Loss in Q1 2026

Amarin Corporation plc reported its financial results for the first quarter of 2026, revealing a total revenue of $45.1 million, a 7.4% increase from $42.0 million in the same period last year. The growth was primarily driven by product revenue, which rose to $43.3 million from $41.0 million year-over-year. However, the company experienced a net loss of $10.5 million, a notable improvement compared to the $15.7 million loss reported in the first quarter of 2025. This resulted in a loss per ordinary share of $0.03, compared to a loss of $0.04 per share in the prior year.

In terms of operational metrics, Amarin's gross margin decreased to 39.4% from 59.8% in the previous year, largely due to an increase in the cost of goods sold, which rose to $27.4 million from $16.9 million. The company’s total operating expenses also decreased significantly to $29.1 million from $41.9 million, reflecting a reduction in selling, general, and administrative expenses, which fell to $21.1 million from $36.6 million. This reduction was attributed to ongoing restructuring efforts aimed at streamlining operations and reducing costs.

Amarin has been actively pursuing strategic partnerships and licensing agreements to enhance its market presence. Notably, the company entered into a long-term licensing agreement with Recordati for the commercialization of VASCEPA in 59 countries across Europe. This agreement is expected to bolster Amarin's revenue streams and expand its market reach. Additionally, the company reported a successful launch of VASCEPA in Mainland China through its partner Eddingpharm, which commenced commercial operations in October 2023.

As of March 31, 2026, Amarin's total assets stood at $645.8 million, a decrease from $670.8 million at the end of 2025. The company maintained a strong cash position with $131.1 million in cash and cash equivalents, alongside $176.8 million in short-term investments. The total liabilities decreased to $196.4 million from $211.5 million, reflecting the company's efforts to manage its financial obligations effectively. The employee headcount remained stable, with no significant changes reported during the quarter.

Looking ahead, Amarin expressed optimism about its growth trajectory, particularly with the anticipated revenue from the Recordati partnership and the ongoing commercialization of VASCEPA in new markets. The company is focused on executing its restructuring plan and enhancing operational efficiencies to improve profitability. Amarin's management remains committed to navigating the competitive landscape of the pharmaceutical industry while continuing to invest in the development of its product pipeline.